These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9372349)

  • 41. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
    Elewski BE; Aly R; Baldwin SL; González Soto RF; Rich P; Weisfeld M; Wiltz H; Zane LT; Pollak R
    J Am Acad Dermatol; 2015 Jul; 73(1):62-9. PubMed ID: 25956661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of onychomycosis with terbinafine.
    Baudraz-Rosselet F; Rakosi T; Wili PB; Kenzelmann R
    Br J Dermatol; 1992 Feb; 126 Suppl 39():40-6. PubMed ID: 1531928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toenail onychomycosis in diabetic patients: issues and management.
    Mayser P; Freund V; Budihardja D
    Am J Clin Dermatol; 2009; 10(4):211-20. PubMed ID: 19489654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Onychomycosis: rationalization of topical treatment.
    Shemer A; Trau H; Davidovici B; Amichai B; Grunwald MH
    Isr Med Assoc J; 2008 Jun; 10(6):415-6. PubMed ID: 18669135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measuring health-related quality of life in onychomycosis.
    Lubeck DP
    J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S64-8. PubMed ID: 9594940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group.
    Tausch I; Bräutigam M; Weidinger G; Jones TC
    Br J Dermatol; 1997 May; 136(5):737-42. PubMed ID: 9205509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.
    Warshaw EM; Fett DD; Bloomfield HE; Grill JP; Nelson DB; Quintero V; Carver SM; Zielke GR; Lederle FA
    J Am Acad Dermatol; 2005 Oct; 53(4):578-84. PubMed ID: 16198776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled study.
    Lahfa M; Bulai-Livideanu C; Baran R; Ortonne JP; Richert B; Tosti A; Piraccini BM; Szepietowski JC; Sibaud V; Coubetergues H; Voisard JJ; Paul C
    Dermatology; 2013; 226(1):5-12. PubMed ID: 23467055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Onychomycosis is no longer a rare finding in children.
    Lange M; Roszkiewicz J; Szczerkowska-Dobosz A; Jasiel-Walikowska E; Bykowska B
    Mycoses; 2006 Jan; 49(1):55-9. PubMed ID: 16367820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients.
    Szepietowski JC; Reich A; Garlowska E; Kulig M; Baran E;
    Arch Dermatol; 2006 Oct; 142(10):1279-84. PubMed ID: 17043182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays.
    Sigurgeirsson B; Ghannoum MA; Osman-Ponchet H; Kerrouche N; Sidou F
    Mycoses; 2016 May; 59(5):319-26. PubMed ID: 26867498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes.
    Vlahovic TC
    Clin Podiatr Med Surg; 2016 Jul; 33(3):305-18. PubMed ID: 27215153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Onychomycosis: multicentre epidemiological, clinical and mycological study].
    Relloso S; Arechavala A; Guelfand L; Maldonado I; Walker L; Agorio I; Reyes S; Giusiano G; Rojas F; Flores V; Capece P; Posse G; Nicola F; Tutzer S; Bianchi M
    Rev Iberoam Micol; 2012; 29(3):157-63. PubMed ID: 22198612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is this toenail condition threatening?
    Monroe JR
    JAAPA; 2012 Jul; 25(7):16. PubMed ID: 22894027
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective.
    Einarson TR; Arikian SR; Shear NH
    Br J Dermatol; 1994 Apr; 130 Suppl 43():32-4. PubMed ID: 8186140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Onychomycosis: burden of disease and the role of topical antifungal treatment.
    Daniel RC
    J Drugs Dermatol; 2013 Nov; 12(11):1263-6. PubMed ID: 24196334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients.
    Cook-Bolden FE; Lin T
    Cutis; 2017 Apr; 99(4):286-289. PubMed ID: 28492600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis.
    Bonifaz A; Guzmán A; Garcia C; Sosa J; Saúl A
    Int J Dermatol; 1995 Jul; 34(7):500-3. PubMed ID: 7591419
    [No Abstract]   [Full Text] [Related]  

  • 59. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis.
    Waibel J; Wulkan AJ; Rudnick A
    J Drugs Dermatol; 2013 Nov; 12(11):1237-42. PubMed ID: 24196331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Topical therapy for toenail onychomycosis: an evidence-based review.
    Gupta AK; Daigle D; Foley KA
    Am J Clin Dermatol; 2014 Dec; 15(6):489-502. PubMed ID: 25257931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.